Cross Country Healthcare filings document the regulatory record for a Nasdaq-listed healthcare workforce solutions company with common stock registered under CCRN. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD communications, material agreements, executive appointments and departures, compensation arrangements and other governance matters.
Proxy and shareholder materials describe director elections, voting matters, executive compensation, board governance and capital-structure information. The filing record also covers the company’s staffing, recruitment, advisory and Intellify platform activities through business updates and financial disclosures tied to healthcare labor markets and technology-enabled workforce management.
Cross Country Healthcare, Inc. disclosed that under its Merger Agreement with Aya Holdings II Inc., the contractual “End Date” for completing their planned merger was automatically extended from September 3, 2025 to December 3, 2025. All other terms of the Merger Agreement remain unchanged.
The company and Aya have each certified to the U.S. Federal Trade Commission that they have substantially complied with the agency’s “Second Request” for additional information related to the transaction. Subject to customary closing conditions and required regulatory approvals, the merger is now expected to close in the fourth quarter of 2025.
Cross Country Healthcare disclosed that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly hold 1,887,473.57 shares of its common stock, equal to 5.8% of the class. The filing identifies GS Group as a parent holding company and Goldman Sachs & Co. LLC as a broker-dealer and registered investment adviser that may own the securities on the parent’s behalf. The reporting parties certify the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing includes a joint filing agreement and an exhibit identifying the subsidiary relationship.
Cross Country Healthcare (CCRN) Q2 2025 10-Q highlights:
- Revenue fell 19.3 % YoY to $274.1 million; six-month revenue declined 21.1 % to $567.5 million as travel-nurse volumes and bill rates continued to normalize.
- Loss from operations narrowed to $5.9 million (vs. $19.2 million loss LY). Net loss improved to $6.7 million or -$0.20 EPS (LY: -$0.47).
- Gross margin slipped 30 bp YoY to 20.4 % as lower pricing offset cost controls; SG&A down 17 % to $50.1 million.
- Operating cash flow was positive at $9.9 million YTD but sharply below $88.4 million LY, reflecting lower earnings and working-capital unwind.
- Balance sheet remains debt-free; cash & equivalents stable at $81.2 million. Equity totals $412.2 million (book value ≈ $12.7/share).
- Aya Healthcare take-private deal progressing: FTC issued a Second Request on 20 Feb 2025; close expected 4Q 2025. CCRN incurred $6.0 million Q2 and $8.0 million YTD in merger-related costs.
- Segments: Nurse & Allied supplied 82 % of revenue, down 23 %. Physician Staffing rose 3 % YoY.
- No share repurchases in Q2; $40.5 million remains authorized.
Key takeaways: While demand headwinds continue to pressure top line, CCRN preserved liquidity, maintained a debt-free balance sheet, and reduced losses. Future value for shareholders now hinges on successful completion of the Aya merger and potential go-private premium.